AbbVie Inc. (ABBV) is a publicly traded company in the Healthcare — Drug Manufacturers - General industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active...
Analysis Summary
AbbVie Inc. reported revenue of $61.16B in the most recent fiscal year, growing at a 5-year CAGR of 6.0%. Net income reached $4.23B, with a -1.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 71.5%, operating margin 29.3%, net margin 9.8%. Free cash flow grew at 1.2% CAGR over 5 years.
At the current price of $262.58, ABBV trades at a P/E of 73.77 and an ROE of -129.24%. Market capitalisation stands at $463.9B, placing it among large-cap names.
Balance sheet quality for ABBV: current ratio of 0.7, net debt of $63.81B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $17.82B represents 422% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $262.58 |
| Market Cap | $463.9B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 73.77 |
| Price / Book | -78.14 |
| EV / EBITDA | 26.61 |
| Dividend Yield | 2.61% |
Profitability
| Return on Equity | -129.24% |
| Return on Invested Capital | 12.97% |
| Return on Assets | 3.15% |
| Gross Margin | 71.48% |
| Operating Margin | 29.32% |
| Net Margin | 9.81% |
Financial Health
| Debt / Equity | -11.93 |
| Current Ratio | 0.81 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.43 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | $445.7B | 73.77 | -129.2% | |
| MRK | Merck & Co., Inc. | $355.5B | 115.04 | 8.54 | 6.6% |
| AMGN | Amgen Inc. | $203.1B | 23.20 | 17.39 | 89.3% |
| GILD | Gilead Sciences, Inc. | $183.4B | 15.77 | -16.3% | |
| JNJ | Johnson & Johnson | $644.1B | 30.82 | 7.66 | 25.7% |
| AZN | AstraZeneca PLC | $252.6B | 25.10 | 5.17 | 21.7% |
| NVS | Novartis AG | $263.6B | 21.26 | 6.41 | 29.6% |
| NVO | Novo Nordisk A/S | $185.3B | 9.72 | 5.10 | 59.1% |
Price Performance
| 1 month | +1.41% |
| 3 months | +21.29% |
| Year-to-date | +14.92% |
| 1 year | +18.92% |
| 3 years | +70.57% |
| 5 years | +143.74% |
52-Week Range
| 52-week High | $267.47 |
| 52-week Low | $190.75 |
| Avg Volume (90d) | 6.0M |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2026-10-15 | $1.7300 | 2.64% |
| 2026-07-15 | $1.7300 | 2.64% |
| 2026-04-15 | $1.7300 | 2.64% |
| 2026-01-16 | $1.7300 | 2.64% |
| 2025-10-15 | $1.6400 | 2.50% |
| 2025-07-15 | $1.6400 | 2.50% |
| 2025-04-15 | $1.6400 | 2.50% |
| 2025-01-15 | $1.6400 | 2.50% |
| 2024-10-15 | $1.5500 | 2.36% |
| 2024-07-15 | $1.5500 | 2.36% |
Related companies: AMGN · AZN · GILD · JNJ · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of ABBV: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks